The value of the xB3 platform is the potential it has to turn non-brain-penetrating drugs into novel medical entities. The xB3 platform presents the opportunity to deliver medicines into the brain that were previously ineffective in treating the neurological aspects of a disease in a noninvasive manner. Like a key designed to open a lock, the xB3 platform unlocks the door to the blood-brain barrier, allowing entry of therapeutics into the brain.
Looks like xB3 is a ute which can carry anticncer drugs across the BBB.
PAT-DX1 is a guided missile which has been shown in pre-clinical trials to cross the BBB, target and enter the cancer cells, and disrupt the DNA damage repair (DDR) system all on its own. It can also preferentially transport anticancer drugs and radiation targets to enter cancer calls.
Lets hope the clinical trials are as good as the pre-clinical trials.
PAB Price at posting:
5.1¢ Sentiment: Buy Disclosure: Held
